Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Resistance, Neoplasm | 37 | 2024 | 5305 | 2.560 |
Why?
|
Genomics | 44 | 2024 | 5821 | 2.450 |
Why?
|
Carcinoma, Renal Cell | 28 | 2024 | 3164 | 2.250 |
Why?
|
Neoplasms | 46 | 2024 | 22170 | 2.040 |
Why?
|
Kidney Neoplasms | 28 | 2024 | 4249 | 2.040 |
Why?
|
Medical Oncology | 14 | 2024 | 2321 | 1.740 |
Why?
|
Immunotherapy | 26 | 2024 | 4652 | 1.720 |
Why?
|
Prostatic Neoplasms | 32 | 2024 | 11118 | 1.690 |
Why?
|
Urinary Bladder Neoplasms | 15 | 2024 | 2223 | 1.660 |
Why?
|
Receptors, Androgen | 11 | 2022 | 1079 | 1.440 |
Why?
|
Germ-Line Mutation | 17 | 2022 | 1858 | 1.430 |
Why?
|
Melanoma | 17 | 2024 | 5709 | 1.340 |
Why?
|
Antigens, Neoplasm | 9 | 2019 | 1993 | 1.340 |
Why?
|
Mutation | 73 | 2024 | 30052 | 1.290 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 4 | 2023 | 491 | 1.150 |
Why?
|
DNA Repair | 11 | 2021 | 2045 | 1.130 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 7 | 2023 | 106 | 1.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 20 | 2022 | 3639 | 0.980 |
Why?
|
Antigen Presentation | 7 | 2021 | 1251 | 0.970 |
Why?
|
Antineoplastic Agents | 24 | 2023 | 13639 | 0.950 |
Why?
|
Proto-Oncogene Proteins B-raf | 8 | 2020 | 2057 | 0.910 |
Why?
|
DNA Repair-Deficiency Disorders | 2 | 2021 | 37 | 0.910 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2024 | 11742 | 0.900 |
Why?
|
DNA Mutational Analysis | 10 | 2022 | 4111 | 0.880 |
Why?
|
Carcinoma, Transitional Cell | 5 | 2022 | 782 | 0.850 |
Why?
|
Androgen Antagonists | 6 | 2023 | 1410 | 0.840 |
Why?
|
Tumor Microenvironment | 16 | 2024 | 3877 | 0.840 |
Why?
|
Urologic Neoplasms | 5 | 2020 | 314 | 0.830 |
Why?
|
Genome, Human | 13 | 2021 | 4425 | 0.790 |
Why?
|
Gene Expression Regulation, Neoplastic | 17 | 2024 | 8547 | 0.770 |
Why?
|
Neurofibromin 1 | 2 | 2020 | 190 | 0.750 |
Why?
|
Humans | 235 | 2024 | 761504 | 0.740 |
Why?
|
Carcinoma | 3 | 2023 | 2330 | 0.730 |
Why?
|
Artificial Intelligence | 7 | 2024 | 2578 | 0.730 |
Why?
|
Sequence Analysis, DNA | 15 | 2021 | 4740 | 0.720 |
Why?
|
Lung Neoplasms | 14 | 2024 | 13380 | 0.720 |
Why?
|
Genetic Testing | 5 | 2024 | 3537 | 0.710 |
Why?
|
PTEN Phosphohydrolase | 6 | 2020 | 1115 | 0.670 |
Why?
|
Gene Expression Profiling | 17 | 2021 | 9420 | 0.660 |
Why?
|
Gene Fusion | 2 | 2022 | 356 | 0.650 |
Why?
|
Testicular Neoplasms | 4 | 2021 | 799 | 0.640 |
Why?
|
GTP Phosphohydrolases | 3 | 2021 | 517 | 0.640 |
Why?
|
Protein Kinase Inhibitors | 13 | 2022 | 5671 | 0.620 |
Why?
|
Skin Neoplasms | 9 | 2024 | 5821 | 0.610 |
Why?
|
Neoadjuvant Therapy | 11 | 2024 | 2827 | 0.610 |
Why?
|
Cisplatin | 6 | 2023 | 1651 | 0.610 |
Why?
|
Neoplasm Metastasis | 21 | 2024 | 4915 | 0.600 |
Why?
|
Databases, Genetic | 10 | 2021 | 1742 | 0.580 |
Why?
|
Radiation Tolerance | 2 | 2019 | 479 | 0.580 |
Why?
|
Data Display | 1 | 2018 | 175 | 0.580 |
Why?
|
Microsatellite Repeats | 2 | 2018 | 784 | 0.550 |
Why?
|
Leiomyosarcoma | 2 | 2019 | 422 | 0.540 |
Why?
|
Oncogenes | 2 | 2022 | 1222 | 0.530 |
Why?
|
Genetic Predisposition to Disease | 21 | 2024 | 17904 | 0.520 |
Why?
|
Inheritance Patterns | 1 | 2018 | 341 | 0.510 |
Why?
|
Genome | 4 | 2020 | 1740 | 0.510 |
Why?
|
Tumor Suppressor Protein p53 | 10 | 2022 | 2917 | 0.510 |
Why?
|
Introns | 1 | 2018 | 981 | 0.510 |
Why?
|
Adenocarcinoma | 8 | 2020 | 6346 | 0.500 |
Why?
|
Cell Line, Tumor | 27 | 2024 | 16981 | 0.500 |
Why?
|
Janus Kinase 3 | 1 | 2015 | 76 | 0.490 |
Why?
|
Paternal Exposure | 1 | 2015 | 96 | 0.490 |
Why?
|
Epitopes | 2 | 2018 | 2503 | 0.480 |
Why?
|
Biomarkers, Pharmacological | 1 | 2015 | 161 | 0.480 |
Why?
|
Male | 110 | 2024 | 360804 | 0.470 |
Why?
|
Germ Cells | 7 | 2022 | 634 | 0.460 |
Why?
|
Immunoconjugates | 1 | 2022 | 954 | 0.460 |
Why?
|
Prostate-Specific Antigen | 4 | 2023 | 2469 | 0.460 |
Why?
|
Drug Synergism | 2 | 2016 | 1755 | 0.450 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1787 | 0.450 |
Why?
|
Sarcoma | 2 | 2022 | 1801 | 0.440 |
Why?
|
Immunologic Factors | 3 | 2022 | 1589 | 0.440 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 477 | 0.440 |
Why?
|
Tongue Neoplasms | 1 | 2015 | 183 | 0.430 |
Why?
|
Neoplasm Proteins | 6 | 2024 | 3617 | 0.420 |
Why?
|
Repressor Proteins | 2 | 2021 | 2986 | 0.420 |
Why?
|
TOR Serine-Threonine Kinases | 7 | 2020 | 2057 | 0.420 |
Why?
|
Nuclear Proteins | 5 | 2024 | 5796 | 0.410 |
Why?
|
Molecular Targeted Therapy | 11 | 2024 | 2811 | 0.410 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 1745 | 0.400 |
Why?
|
Urothelium | 1 | 2014 | 269 | 0.400 |
Why?
|
Cell Survival | 2 | 2021 | 5791 | 0.390 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 410 | 0.390 |
Why?
|
Bone Neoplasms | 5 | 2024 | 2529 | 0.390 |
Why?
|
Urinary Bladder | 1 | 2017 | 1152 | 0.380 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5789 | 0.380 |
Why?
|
Phosphatidylinositol 3-Kinases | 7 | 2018 | 2865 | 0.370 |
Why?
|
Thyroid Neoplasms | 2 | 2022 | 2332 | 0.370 |
Why?
|
Mouth Neoplasms | 2 | 2018 | 596 | 0.360 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1157 | 0.350 |
Why?
|
Prostate | 3 | 2022 | 1770 | 0.350 |
Why?
|
Signal Transduction | 16 | 2021 | 23445 | 0.350 |
Why?
|
Colorectal Neoplasms | 7 | 2021 | 6935 | 0.340 |
Why?
|
Ketones | 2 | 2021 | 184 | 0.340 |
Why?
|
Furans | 2 | 2021 | 202 | 0.340 |
Why?
|
Transcription, Genetic | 4 | 2021 | 7594 | 0.340 |
Why?
|
DNA, Neoplasm | 5 | 2018 | 1745 | 0.330 |
Why?
|
Endogenous Retroviruses | 2 | 2022 | 111 | 0.320 |
Why?
|
Biopsy | 7 | 2024 | 6766 | 0.320 |
Why?
|
Ovarian Neoplasms | 2 | 2023 | 4876 | 0.320 |
Why?
|
Cell Cycle Proteins | 4 | 2024 | 3448 | 0.320 |
Why?
|
Cystectomy | 3 | 2024 | 634 | 0.310 |
Why?
|
T-Lymphocytes | 8 | 2024 | 10194 | 0.310 |
Why?
|
Middle Aged | 62 | 2024 | 220895 | 0.310 |
Why?
|
Models, Genetic | 1 | 2018 | 3442 | 0.300 |
Why?
|
Uterine Neoplasms | 1 | 2017 | 1420 | 0.300 |
Why?
|
Treatment Refusal | 1 | 2011 | 429 | 0.300 |
Why?
|
Software | 3 | 2020 | 4434 | 0.290 |
Why?
|
Antibodies, Monoclonal | 6 | 2024 | 9177 | 0.290 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 5315 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4026 | 0.290 |
Why?
|
Membrane Proteins | 4 | 2021 | 7856 | 0.290 |
Why?
|
Aged | 52 | 2024 | 169289 | 0.280 |
Why?
|
Gene Dosage | 4 | 2021 | 1217 | 0.280 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2022 | 1092 | 0.280 |
Why?
|
Physician-Patient Relations | 2 | 2011 | 3249 | 0.280 |
Why?
|
Anus Neoplasms | 2 | 2024 | 329 | 0.280 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2024 | 305 | 0.270 |
Why?
|
Prostatectomy | 5 | 2023 | 1824 | 0.270 |
Why?
|
Female | 73 | 2024 | 392644 | 0.270 |
Why?
|
Neoplasm Invasiveness | 7 | 2023 | 3595 | 0.270 |
Why?
|
Sulfonamides | 4 | 2018 | 1978 | 0.270 |
Why?
|
Phenylthiohydantoin | 4 | 2021 | 205 | 0.270 |
Why?
|
DNA Mismatch Repair | 2 | 2019 | 428 | 0.260 |
Why?
|
Melanoma, Experimental | 2 | 2020 | 560 | 0.250 |
Why?
|
Computer Simulation | 2 | 2018 | 6240 | 0.250 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2018 | 946 | 0.250 |
Why?
|
Patient Care | 1 | 2011 | 622 | 0.250 |
Why?
|
DNA Copy Number Variations | 8 | 2023 | 2020 | 0.250 |
Why?
|
Breast Neoplasms | 9 | 2024 | 21012 | 0.250 |
Why?
|
Tumor Escape | 2 | 2018 | 370 | 0.240 |
Why?
|
Cohort Studies | 17 | 2022 | 41487 | 0.240 |
Why?
|
Neuroendocrine Tumors | 3 | 2023 | 641 | 0.240 |
Why?
|
Death | 1 | 2009 | 676 | 0.240 |
Why?
|
Neoplasm Staging | 8 | 2024 | 11121 | 0.240 |
Why?
|
Genetic Heterogeneity | 5 | 2024 | 732 | 0.240 |
Why?
|
Transcription Factors | 9 | 2023 | 12128 | 0.230 |
Why?
|
Phthalazines | 2 | 2024 | 383 | 0.230 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 2538 | 0.230 |
Why?
|
Ploidies | 1 | 2024 | 285 | 0.230 |
Why?
|
DNA Damage | 4 | 2022 | 2446 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 7 | 2024 | 4580 | 0.230 |
Why?
|
Genomic Structural Variation | 1 | 2024 | 68 | 0.230 |
Why?
|
Computational Biology | 6 | 2024 | 3518 | 0.230 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2020 | 3602 | 0.230 |
Why?
|
Genome-Wide Association Study | 6 | 2022 | 12690 | 0.220 |
Why?
|
Cyclic AMP Response Element-Binding Protein A | 2 | 2022 | 21 | 0.220 |
Why?
|
Radium | 1 | 2024 | 72 | 0.220 |
Why?
|
Platinum | 2 | 2022 | 220 | 0.210 |
Why?
|
Aged, 80 and over | 24 | 2024 | 58976 | 0.210 |
Why?
|
Tumor Suppressor Proteins | 6 | 2024 | 2803 | 0.210 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2021 | 257 | 0.210 |
Why?
|
Nitriles | 4 | 2021 | 971 | 0.210 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 2021 | 641 | 0.210 |
Why?
|
Allergy and Immunology | 1 | 2024 | 176 | 0.210 |
Why?
|
MAP Kinase Signaling System | 4 | 2018 | 1486 | 0.200 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2022 | 43 | 0.200 |
Why?
|
Benzamides | 4 | 2021 | 1370 | 0.200 |
Why?
|
Proto-Oncogene Proteins | 3 | 2021 | 4511 | 0.200 |
Why?
|
Attitude to Health | 1 | 2011 | 2025 | 0.200 |
Why?
|
Antigen-Antibody Complex | 1 | 2024 | 510 | 0.200 |
Why?
|
Microphthalmia-Associated Transcription Factor | 2 | 2022 | 259 | 0.200 |
Why?
|
Genes, Neoplasm | 3 | 2018 | 370 | 0.190 |
Why?
|
Stomach Neoplasms | 2 | 2023 | 1459 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 205 | 0.190 |
Why?
|
Adult | 38 | 2024 | 221177 | 0.190 |
Why?
|
Intestinal Neoplasms | 1 | 2023 | 312 | 0.180 |
Why?
|
Alkylating Agents | 1 | 2021 | 133 | 0.180 |
Why?
|
Multiple Myeloma | 4 | 2020 | 5146 | 0.180 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2020 | 899 | 0.180 |
Why?
|
Osteosarcoma | 2 | 2018 | 897 | 0.180 |
Why?
|
False Positive Reactions | 2 | 2016 | 957 | 0.180 |
Why?
|
Microsatellite Instability | 3 | 2020 | 716 | 0.180 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 117 | 0.180 |
Why?
|
Androgens | 3 | 2023 | 1286 | 0.180 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2895 | 0.180 |
Why?
|
Estrogen Receptor alpha | 1 | 2014 | 582 | 0.180 |
Why?
|
Pyrimidinones | 2 | 2020 | 385 | 0.170 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2021 | 198 | 0.170 |
Why?
|
Therapies, Investigational | 1 | 2021 | 111 | 0.170 |
Why?
|
Epigenesis, Genetic | 5 | 2024 | 3802 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 382 | 0.170 |
Why?
|
Sesquiterpenes | 1 | 2020 | 176 | 0.170 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 306 | 0.170 |
Why?
|
Morpholines | 2 | 2020 | 581 | 0.170 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2020 | 126 | 0.170 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2629 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 318 | 0.160 |
Why?
|
Carboplatin | 1 | 2022 | 794 | 0.160 |
Why?
|
Cardiology | 1 | 2010 | 1656 | 0.160 |
Why?
|
Paraffin Embedding | 1 | 2020 | 302 | 0.160 |
Why?
|
Tissue Fixation | 1 | 2020 | 241 | 0.160 |
Why?
|
Gene Amplification | 2 | 2021 | 1089 | 0.160 |
Why?
|
Muscles | 5 | 2022 | 1576 | 0.160 |
Why?
|
Histone Demethylases | 2 | 2020 | 320 | 0.160 |
Why?
|
Disease Progression | 8 | 2023 | 13506 | 0.160 |
Why?
|
Survival Analysis | 8 | 2021 | 10090 | 0.160 |
Why?
|
raf Kinases | 2 | 2016 | 118 | 0.160 |
Why?
|
Aminopyridines | 2 | 2020 | 573 | 0.160 |
Why?
|
Animals | 28 | 2024 | 168459 | 0.160 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 101 | 0.160 |
Why?
|
Androgen Receptor Antagonists | 1 | 2019 | 125 | 0.160 |
Why?
|
Watchful Waiting | 1 | 2023 | 491 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
Biology | 1 | 2021 | 290 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2018 | 350 | 0.160 |
Why?
|
Multifactorial Inheritance | 2 | 2024 | 1387 | 0.160 |
Why?
|
Epigenomics | 1 | 2024 | 943 | 0.150 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
RNA-Induced Silencing Complex | 1 | 2018 | 56 | 0.150 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2022 | 790 | 0.150 |
Why?
|
Algorithms | 4 | 2018 | 14031 | 0.150 |
Why?
|
Gene Library | 1 | 2021 | 1059 | 0.150 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 179 | 0.150 |
Why?
|
Quality Control | 1 | 2021 | 832 | 0.150 |
Why?
|
Mice | 21 | 2024 | 81525 | 0.150 |
Why?
|
Proteome | 2 | 2021 | 1862 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2018 | 561 | 0.150 |
Why?
|
Prospective Studies | 11 | 2024 | 54425 | 0.150 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 2 | 2022 | 164 | 0.150 |
Why?
|
Pyrazoles | 2 | 2020 | 2009 | 0.150 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2021 | 339 | 0.140 |
Why?
|
Epitope Mapping | 1 | 2018 | 298 | 0.140 |
Why?
|
DNA-Binding Proteins | 6 | 2022 | 9606 | 0.140 |
Why?
|
Terminal Care | 1 | 2009 | 1760 | 0.140 |
Why?
|
Spliceosomes | 1 | 2018 | 130 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2021 | 9280 | 0.140 |
Why?
|
Nucleotides | 1 | 2020 | 454 | 0.140 |
Why?
|
Treatment Outcome | 16 | 2024 | 64680 | 0.140 |
Why?
|
Immunity, Cellular | 2 | 2020 | 1560 | 0.140 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2017 | 51 | 0.140 |
Why?
|
Cullin Proteins | 1 | 2018 | 179 | 0.140 |
Why?
|
Electron Transport Complex I | 1 | 2018 | 153 | 0.140 |
Why?
|
Students, Medical | 1 | 2010 | 1936 | 0.140 |
Why?
|
Pyrimidines | 3 | 2024 | 3028 | 0.140 |
Why?
|
Phenotype | 6 | 2023 | 16591 | 0.140 |
Why?
|
Prognosis | 15 | 2023 | 29625 | 0.140 |
Why?
|
Adenoma, Oxyphilic | 1 | 2018 | 148 | 0.140 |
Why?
|
Liposarcoma | 1 | 2019 | 289 | 0.130 |
Why?
|
Bone Marrow Neoplasms | 1 | 2017 | 101 | 0.130 |
Why?
|
Receptors, Estrogen | 3 | 2021 | 2208 | 0.130 |
Why?
|
Pancreatic Neoplasms | 2 | 2024 | 5368 | 0.130 |
Why?
|
Indoles | 2 | 2015 | 1833 | 0.130 |
Why?
|
Survival Rate | 6 | 2021 | 12725 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2021 | 423 | 0.130 |
Why?
|
Radiation Oncology | 1 | 2022 | 563 | 0.130 |
Why?
|
Quinoxalines | 1 | 2018 | 296 | 0.130 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 736 | 0.130 |
Why?
|
Data Mining | 1 | 2021 | 551 | 0.130 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 223 | 0.130 |
Why?
|
Immunity | 2 | 2019 | 996 | 0.130 |
Why?
|
Glutathione | 1 | 2018 | 583 | 0.130 |
Why?
|
Lysine | 1 | 2020 | 993 | 0.130 |
Why?
|
Electronic Health Records | 6 | 2023 | 4811 | 0.130 |
Why?
|
Cerebellar Neoplasms | 1 | 2020 | 586 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2023 | 3492 | 0.130 |
Why?
|
Immunologic Surveillance | 1 | 2016 | 92 | 0.130 |
Why?
|
Immunohistochemistry | 5 | 2020 | 11076 | 0.130 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2015 | 332 | 0.130 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2020 | 1693 | 0.130 |
Why?
|
Proteins | 2 | 2021 | 6032 | 0.130 |
Why?
|
Oximes | 2 | 2013 | 303 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 1520 | 0.120 |
Why?
|
Medulloblastoma | 1 | 2020 | 678 | 0.120 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2016 | 255 | 0.120 |
Why?
|
Oncogene Proteins | 2 | 2020 | 718 | 0.120 |
Why?
|
Pyrrolidinones | 1 | 2015 | 116 | 0.120 |
Why?
|
Stress, Psychological | 1 | 2010 | 4481 | 0.120 |
Why?
|
RNA | 3 | 2022 | 2726 | 0.120 |
Why?
|
HEK293 Cells | 2 | 2014 | 4278 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 1551 | 0.120 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2019 | 633 | 0.120 |
Why?
|
Radiosurgery | 1 | 2024 | 1342 | 0.120 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 662 | 0.120 |
Why?
|
Deoxycytidine | 2 | 2017 | 877 | 0.120 |
Why?
|
Mitochondria | 2 | 2018 | 3624 | 0.110 |
Why?
|
Uveal Neoplasms | 1 | 2017 | 341 | 0.110 |
Why?
|
Reproducibility of Results | 4 | 2021 | 20098 | 0.110 |
Why?
|
Documentation | 1 | 2020 | 897 | 0.110 |
Why?
|
Gene Silencing | 1 | 2020 | 1509 | 0.110 |
Why?
|
Indazoles | 3 | 2024 | 304 | 0.110 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2013 | 92 | 0.110 |
Why?
|
Teratoma | 1 | 2016 | 404 | 0.110 |
Why?
|
Androstenes | 2 | 2019 | 181 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1606 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2523 | 0.110 |
Why?
|
Mass Screening | 1 | 2009 | 5428 | 0.110 |
Why?
|
Phylogeny | 2 | 2021 | 2811 | 0.110 |
Why?
|
History, 21st Century | 1 | 2019 | 1567 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2023 | 1626 | 0.100 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2012 | 30 | 0.100 |
Why?
|
Comprehension | 1 | 2018 | 621 | 0.100 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2018 | 727 | 0.100 |
Why?
|
Aptamers, Nucleotide | 1 | 2013 | 165 | 0.100 |
Why?
|
Incidental Findings | 2 | 2016 | 697 | 0.100 |
Why?
|
Testis | 1 | 2015 | 794 | 0.100 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2015 | 504 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2018 | 2571 | 0.100 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 7390 | 0.100 |
Why?
|
Risk Factors | 8 | 2024 | 74206 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1613 | 0.100 |
Why?
|
Mediator Complex | 1 | 2012 | 106 | 0.100 |
Why?
|
Disease Models, Animal | 4 | 2024 | 18252 | 0.100 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2013 | 779 | 0.100 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15266 | 0.100 |
Why?
|
Ubiquitin Thiolesterase | 3 | 2021 | 455 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2018 | 1897 | 0.100 |
Why?
|
Microtubule-Associated Proteins | 2 | 2018 | 1076 | 0.100 |
Why?
|
Retrospective Studies | 12 | 2024 | 80636 | 0.100 |
Why?
|
Spermatozoa | 1 | 2015 | 630 | 0.100 |
Why?
|
Anecdotes as Topic | 1 | 2011 | 56 | 0.090 |
Why?
|
Evolution, Molecular | 2 | 2016 | 1886 | 0.090 |
Why?
|
Mice, Inbred NOD | 3 | 2020 | 1827 | 0.090 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2017 | 1349 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3514 | 0.090 |
Why?
|
Conserved Sequence | 1 | 2014 | 1163 | 0.090 |
Why?
|
Young Adult | 12 | 2022 | 59243 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2020 | 5671 | 0.090 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 8002 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2020 | 2049 | 0.090 |
Why?
|
Imidazoles | 2 | 2013 | 1180 | 0.090 |
Why?
|
Cancer Vaccines | 1 | 2018 | 1051 | 0.090 |
Why?
|
Paracentesis | 1 | 2011 | 98 | 0.090 |
Why?
|
Blood Proteins | 1 | 2016 | 1173 | 0.090 |
Why?
|
Sick Role | 1 | 2011 | 229 | 0.090 |
Why?
|
Humanism | 1 | 2011 | 86 | 0.090 |
Why?
|
Metabolomics | 1 | 2019 | 1659 | 0.090 |
Why?
|
Internship and Residency | 1 | 2010 | 5880 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4853 | 0.090 |
Why?
|
HLA Antigens | 1 | 2015 | 1328 | 0.090 |
Why?
|
Lymphocytes | 1 | 2018 | 2612 | 0.090 |
Why?
|
Protein Biosynthesis | 1 | 2017 | 2113 | 0.080 |
Why?
|
Histones | 1 | 2020 | 2580 | 0.080 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2023 | 372 | 0.080 |
Why?
|
Protein Conformation | 2 | 2014 | 3968 | 0.080 |
Why?
|
Quinolines | 1 | 2015 | 764 | 0.080 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 819 | 0.080 |
Why?
|
Proteomics | 2 | 2021 | 3849 | 0.080 |
Why?
|
Androstenols | 1 | 2009 | 25 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2825 | 0.080 |
Why?
|
Risk | 1 | 2021 | 9610 | 0.080 |
Why?
|
Remission Induction | 1 | 2015 | 2396 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2015 | 3597 | 0.080 |
Why?
|
Ketoconazole | 1 | 2009 | 97 | 0.080 |
Why?
|
Mice, Nude | 3 | 2018 | 3615 | 0.080 |
Why?
|
Pyrroles | 1 | 2015 | 1125 | 0.080 |
Why?
|
Neutrophils | 2 | 2019 | 3767 | 0.080 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2416 | 0.080 |
Why?
|
Pedigree | 1 | 2016 | 4542 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2850 | 0.080 |
Why?
|
Research Design | 2 | 2021 | 6180 | 0.080 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 4414 | 0.080 |
Why?
|
Sequence Analysis | 2 | 2022 | 240 | 0.080 |
Why?
|
Natural Language Processing | 3 | 2021 | 1162 | 0.080 |
Why?
|
RNA, Double-Stranded | 2 | 2020 | 294 | 0.070 |
Why?
|
Hormones | 2 | 2022 | 869 | 0.070 |
Why?
|
Chromosome Mapping | 1 | 2016 | 4615 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 698 | 0.070 |
Why?
|
Genes, Tumor Suppressor | 2 | 2024 | 1062 | 0.070 |
Why?
|
Sirolimus | 1 | 2014 | 1533 | 0.070 |
Why?
|
Survivors | 1 | 2018 | 2371 | 0.070 |
Why?
|
Models, Molecular | 2 | 2014 | 5439 | 0.070 |
Why?
|
Quality of Life | 3 | 2024 | 13367 | 0.070 |
Why?
|
Pyridines | 2 | 2018 | 2875 | 0.070 |
Why?
|
Professional-Family Relations | 1 | 2011 | 495 | 0.070 |
Why?
|
Sequence Analysis, RNA | 3 | 2020 | 2020 | 0.070 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2016 | 1073 | 0.070 |
Why?
|
Genetic Variation | 3 | 2016 | 6567 | 0.070 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1768 | 0.070 |
Why?
|
Alleles | 1 | 2017 | 6863 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 2455 | 0.070 |
Why?
|
Medical Informatics | 1 | 2013 | 733 | 0.070 |
Why?
|
DNA Helicases | 2 | 2023 | 851 | 0.070 |
Why?
|
Receptors, Progesterone | 2 | 2021 | 1129 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2011 | 1834 | 0.070 |
Why?
|
Radiography | 2 | 2014 | 6965 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26125 | 0.070 |
Why?
|
Cyclin D1 | 2 | 2018 | 451 | 0.060 |
Why?
|
Professional-Patient Relations | 1 | 2011 | 726 | 0.060 |
Why?
|
DNA Methylation | 4 | 2024 | 4398 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14666 | 0.060 |
Why?
|
Endometrial Neoplasms | 1 | 2014 | 1366 | 0.060 |
Why?
|
Pteridines | 1 | 2014 | 47 | 0.060 |
Why?
|
Europe | 2 | 2024 | 3422 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1897 | 0.060 |
Why?
|
Phosphoproteins | 1 | 2013 | 2448 | 0.060 |
Why?
|
Child | 6 | 2023 | 80153 | 0.060 |
Why?
|
Mice, SCID | 2 | 2020 | 2626 | 0.060 |
Why?
|
RNA Interference | 1 | 2013 | 2831 | 0.060 |
Why?
|
Decision Support Systems, Clinical | 1 | 2013 | 1175 | 0.060 |
Why?
|
Phosphorylation | 1 | 2015 | 8320 | 0.060 |
Why?
|
Receptors, Immunologic | 2 | 2020 | 1410 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5440 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2020 | 15936 | 0.060 |
Why?
|
Up-Regulation | 2 | 2023 | 4124 | 0.060 |
Why?
|
Histone-Lysine N-Methyltransferase | 2 | 2020 | 682 | 0.050 |
Why?
|
INDEL Mutation | 2 | 2015 | 266 | 0.050 |
Why?
|
Interpersonal Relations | 1 | 2011 | 1436 | 0.050 |
Why?
|
Health Surveys | 1 | 2013 | 4061 | 0.050 |
Why?
|
Castration | 1 | 2023 | 151 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4369 | 0.050 |
Why?
|
bcl-X Protein | 1 | 2014 | 410 | 0.050 |
Why?
|
Receptor, erbB-2 | 3 | 2020 | 2557 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2024 | 517 | 0.050 |
Why?
|
Electric Power Supplies | 1 | 2023 | 96 | 0.050 |
Why?
|
HIV Infections | 1 | 2009 | 17351 | 0.050 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2023 | 293 | 0.050 |
Why?
|
Chromosomal Instability | 1 | 2023 | 178 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7581 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4792 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 143 | 0.050 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 243 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 368 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8529 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2024 | 586 | 0.050 |
Why?
|
Credentialing | 1 | 2022 | 116 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2022 | 169 | 0.050 |
Why?
|
Arabs | 1 | 2023 | 187 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 297 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8830 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2016 | 6814 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2020 | 2707 | 0.050 |
Why?
|
Apoptosis | 1 | 2016 | 9486 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 857 | 0.040 |
Why?
|
Dactinomycin | 1 | 2020 | 304 | 0.040 |
Why?
|
Child, Preschool | 3 | 2022 | 42230 | 0.040 |
Why?
|
Random Allocation | 1 | 2014 | 2395 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 156 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4320 | 0.040 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2021 | 361 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20570 | 0.040 |
Why?
|
Histocompatibility Antigens | 1 | 2021 | 464 | 0.040 |
Why?
|
Aneuploidy | 1 | 2023 | 551 | 0.040 |
Why?
|
Societies, Medical | 2 | 2024 | 3905 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 522 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2012 | 4936 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 668 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 367 | 0.040 |
Why?
|
Kynurenine | 1 | 2019 | 141 | 0.040 |
Why?
|
Steroid 16-alpha-Hydroxylase | 1 | 2018 | 12 | 0.040 |
Why?
|
Drugs, Investigational | 1 | 2021 | 212 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6485 | 0.040 |
Why?
|
Databases, Protein | 1 | 2021 | 387 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2471 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 558 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 535 | 0.040 |
Why?
|
Infant | 2 | 2022 | 36192 | 0.040 |
Why?
|
Melanoma-Specific Antigens | 1 | 2018 | 74 | 0.040 |
Why?
|
Chromatin | 2 | 2021 | 2960 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 106 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10209 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 345 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 601 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 328 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 935 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2021 | 369 | 0.040 |
Why?
|
Computer Graphics | 1 | 2019 | 340 | 0.040 |
Why?
|
Tablets | 1 | 2018 | 148 | 0.040 |
Why?
|
Eukaryotic Initiation Factor-1 | 1 | 2017 | 31 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 778 | 0.040 |
Why?
|
Acetylation | 1 | 2020 | 1055 | 0.040 |
Why?
|
Estradiol | 1 | 2014 | 1937 | 0.040 |
Why?
|
Entropy | 1 | 2018 | 210 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 482 | 0.040 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2018 | 244 | 0.040 |
Why?
|
Gene Duplication | 1 | 2018 | 314 | 0.040 |
Why?
|
Veterans | 1 | 2011 | 2647 | 0.040 |
Why?
|
Genes, myc | 1 | 2018 | 390 | 0.030 |
Why?
|
DNA | 2 | 2024 | 7212 | 0.030 |
Why?
|
beta Catenin | 1 | 2022 | 1040 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2019 | 5486 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 194 | 0.030 |
Why?
|
Single-Cell Analysis | 2 | 2019 | 2449 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 2915 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2019 | 815 | 0.030 |
Why?
|
Cell Line | 2 | 2022 | 15601 | 0.030 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2018 | 638 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 330 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1435 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2469 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1552 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3272 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3429 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1203 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1136 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1386 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 988 | 0.030 |
Why?
|
Genes, Neurofibromatosis 2 | 1 | 2015 | 122 | 0.030 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2015 | 23 | 0.030 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 234 | 0.030 |
Why?
|
Anilides | 1 | 2018 | 411 | 0.030 |
Why?
|
Fumarate Hydratase | 1 | 2015 | 52 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2020 | 2115 | 0.030 |
Why?
|
Oncogene Protein p21(ras) | 1 | 2015 | 68 | 0.030 |
Why?
|
Genes, p16 | 1 | 2015 | 160 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2018 | 943 | 0.030 |
Why?
|
Kidney Tubules, Collecting | 1 | 2015 | 162 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 934 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 655 | 0.030 |
Why?
|
Genes, ras | 1 | 2017 | 654 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1522 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7396 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2020 | 974 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1967 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2078 | 0.030 |
Why?
|
Interferon Type I | 1 | 2018 | 562 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2015 | 10445 | 0.030 |
Why?
|
National Human Genome Research Institute (U.S.) | 1 | 2013 | 22 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2015 | 9031 | 0.030 |
Why?
|
Wnt Proteins | 1 | 2018 | 718 | 0.030 |
Why?
|
HeLa Cells | 1 | 2020 | 3093 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2014 | 181 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1320 | 0.030 |
Why?
|
RNA, Neoplasm | 1 | 2016 | 750 | 0.030 |
Why?
|
Interferons | 1 | 2017 | 706 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 22169 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1727 | 0.030 |
Why?
|
Time Factors | 1 | 2015 | 39967 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1150 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2022 | 2909 | 0.030 |
Why?
|
United States | 4 | 2022 | 72334 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1125 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2547 | 0.030 |
Why?
|
Cell Count | 1 | 2017 | 1835 | 0.030 |
Why?
|
DNA, Mitochondrial | 1 | 2018 | 865 | 0.030 |
Why?
|
Adaptation, Physiological | 1 | 2019 | 1301 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1870 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1089 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2665 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2016 | 2748 | 0.030 |
Why?
|
Muscle, Smooth | 1 | 2016 | 926 | 0.030 |
Why?
|
Haplotypes | 1 | 2018 | 2713 | 0.020 |
Why?
|
Leukocytes | 1 | 2020 | 2026 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1363 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2425 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2116 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2015 | 571 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 803 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2022 | 8181 | 0.020 |
Why?
|
Genetics, Medical | 1 | 2013 | 334 | 0.020 |
Why?
|
Stromal Cells | 1 | 2016 | 1330 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2018 | 1961 | 0.020 |
Why?
|
Prevalence | 2 | 2019 | 15732 | 0.020 |
Why?
|
Autophagy | 1 | 2018 | 1326 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1667 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 1972 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6132 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 793 | 0.020 |
Why?
|
Gene Frequency | 1 | 2016 | 3606 | 0.020 |
Why?
|
Biomedical Research | 1 | 2024 | 3429 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6484 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2013 | 2219 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2632 | 0.020 |
Why?
|
Cell Communication | 1 | 2016 | 1657 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1246 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2015 | 1756 | 0.020 |
Why?
|
Demography | 1 | 2013 | 1648 | 0.020 |
Why?
|
NF-kappa B | 1 | 2017 | 2490 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3123 | 0.020 |
Why?
|
Workflow | 1 | 2013 | 851 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39106 | 0.020 |
Why?
|
Protein Binding | 1 | 2021 | 9351 | 0.020 |
Why?
|
Pyridones | 1 | 2013 | 809 | 0.020 |
Why?
|
Genetic Markers | 1 | 2014 | 2601 | 0.020 |
Why?
|
Bone Marrow | 1 | 2018 | 2911 | 0.020 |
Why?
|
Cell Cycle | 1 | 2016 | 2932 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2244 | 0.020 |
Why?
|
Adolescent | 3 | 2022 | 88319 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5869 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11528 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4244 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12990 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3201 | 0.020 |
Why?
|
Patient Preference | 1 | 2013 | 924 | 0.020 |
Why?
|
Rats | 1 | 2022 | 23742 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9539 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8224 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2898 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6990 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2016 | 13446 | 0.020 |
Why?
|
Base Sequence | 1 | 2016 | 12441 | 0.020 |
Why?
|
Family | 1 | 2016 | 3194 | 0.020 |
Why?
|
Liver | 1 | 2020 | 7529 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2015 | 3466 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2016 | 3548 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10766 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14414 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26198 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12795 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22176 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14605 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11903 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18395 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21353 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 23995 | 0.010 |
Why?
|